320 related articles for article (PubMed ID: 16401247)
1. Efficacy of milnacipran on poststroke depression on inpatient rehabilitation.
Yamakawa Y; Satoh S; Sawa S; Ohta H; Asada T
Psychiatry Clin Neurosci; 2005 Dec; 59(6):705-10. PubMed ID: 16401247
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal functional changes, depression, and health-related quality of life among stroke survivors living at home after inpatient rehabilitation.
Mutai H; Furukawa T; Nakanishi K; Hanihara T
Psychogeriatrics; 2016 May; 16(3):185-90. PubMed ID: 26179118
[TBL] [Abstract][Full Text] [Related]
3. Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study.
Paolucci S; Antonucci G; Grasso MG; Morelli D; Troisi E; Coiro P; De Angelis D; Rizzi F; Bragoni M
Cerebrovasc Dis; 2001; 12(3):264-71. PubMed ID: 11641594
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study.
Sato S; Yamakawa Y; Terashima Y; Ohta H; Asada T
Psychiatry Clin Neurosci; 2006 Oct; 60(5):584-9. PubMed ID: 16958942
[TBL] [Abstract][Full Text] [Related]
5. [Experience with ixel (milnacipran hydrochloride) use in the treatment of patients with post-stroke depression].
Gekht AB; Sorokina IB; Bogolepova AN; Gudkova AA
Ter Arkh; 2003; 75(10):34-8. PubMed ID: 14669603
[TBL] [Abstract][Full Text] [Related]
6. Post-stroke depression and functional independence: a conundrum.
Brown C; Hasson H; Thyselius V; Almborg AH
Acta Neurol Scand; 2012 Jul; 126(1):45-51. PubMed ID: 21992112
[TBL] [Abstract][Full Text] [Related]
7. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
8. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
Isaac MT; Isaac MB; Gallo F; Tournoux A
Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
[TBL] [Abstract][Full Text] [Related]
9. [A clinical psychiatric study about post-stroke depression].
Sato S; Yamakawa Y; Terashimai Y; Asada T
Seishin Shinkeigaku Zasshi; 2006; 108(9):906-16. PubMed ID: 17137194
[TBL] [Abstract][Full Text] [Related]
10. Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke: a double-blind randomized placebo-controlled trial.
Tsai CS; Wu CL; Chou SY; Tsang HY; Hung TH; Su JA
Int Clin Psychopharmacol; 2011 Sep; 26(5):263-7. PubMed ID: 21811172
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression.
Kimura M; Kanetani K; Imai R; Suzuki H; Isayama K; Endo S
Int Clin Psychopharmacol; 2002 May; 17(3):121-5. PubMed ID: 11981353
[TBL] [Abstract][Full Text] [Related]
12. Motor and functional recovery in patients with post-stroke depression.
Nannetti L; Paci M; Pasquini J; Lombardi B; Taiti PG
Disabil Rehabil; 2005 Feb; 27(4):170-5. PubMed ID: 15824047
[TBL] [Abstract][Full Text] [Related]
13. Controlled comparison of milnacipran and fluoxetine in major depression.
Ansseau M; Papart P; Troisfontaines B; Bartholomé F; Bataille M; Charles G; Schittecatte M; Darimont P; Devoitille JM; De Wilde J
Psychopharmacology (Berl); 1994 Feb; 114(1):131-7. PubMed ID: 7846195
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
Kanetani K; Kimura M; Endo S
J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711
[TBL] [Abstract][Full Text] [Related]
15. Poststroke depression and its multifactorial nature: results from a prospective longitudinal study.
De Ryck A; Fransen E; Brouns R; Geurden M; Peij D; Mariën P; De Deyn PP; Engelborghs S
J Neurol Sci; 2014 Dec; 347(1-2):159-66. PubMed ID: 25451004
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
Clerc G;
Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
[TBL] [Abstract][Full Text] [Related]
17. LEVOMILNACIPRAN--A SUCCESSOR OF MILNACIPRAN WITH A HIGHER NORADRENERGIC SELECTIVITY.
Zadka Ł; Dziwota E; Olajossy M
Acta Pol Pharm; 2016; 73(2):285-9. PubMed ID: 27180420
[TBL] [Abstract][Full Text] [Related]
18. The effect of early versus late antidepressant treatment on physical impairment associated with poststroke depression: is there a time-related therapeutic window?
Narushima K; Robinson RG
J Nerv Ment Dis; 2003 Oct; 191(10):645-52. PubMed ID: 14555866
[TBL] [Abstract][Full Text] [Related]
19. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine.
Ansseau M; von Frenckell R; Gérard MA; Mertens C; De Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P
Eur Neuropsychopharmacol; 1991 May; 1(2):113-21. PubMed ID: 1821700
[TBL] [Abstract][Full Text] [Related]
20. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
